CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Intravitreal ranibizumab 0.3mgdrug
Likely dose
Intravitreal ranibizumab 0.3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02107131
NCT02107131Phase 4Completed
CompareCT.gov

Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab

California Retina Consultants·interventional·Posted Apr 8, 2014·Updated Dec 19, 2018

In Brief

A Phase 4 clinical trial evaluating Intravitreal ranibizumab 0.3mg for Diabetic Macular Edema. Completed, enrolled 40 participants across 6 sites.

Detailed Summary

Performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on day-to-day visual function in patients with Diabetic Macular Edema (DME).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 8, 2014
Enrollment StartMar 13, 2015
Primary CompletionMay 15, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.2 years ago

Interventions

Intravitreal ranibizumab 0.3mgdrug